Standard
Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. / Vardarli, Irfan; Nauck, Michael A; Köthe, Lars D; Deacon, Carolyn F; Holst, Jens Juul; Schweizer, Anja; Foley, James E.
In:
Journal of Clinical Endocrinology and Metabolism, Vol. 96, No. 4, 2011, p. 945-954.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Vardarli, I, Nauck, MA, Köthe, LD
, Deacon, CF, Holst, JJ, Schweizer, A & Foley, JE 2011, '
Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes',
Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 4, pp. 945-954.
https://doi.org/10.1210/jc.2010-2178APA
Vardarli, I., Nauck, M. A., Köthe, L. D.
, Deacon, C. F., Holst, J. J., Schweizer, A., & Foley, J. E. (2011).
Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.
Journal of Clinical Endocrinology and Metabolism,
96(4), 945-954.
https://doi.org/10.1210/jc.2010-2178Vancouver
Vardarli I, Nauck MA, Köthe LD
, Deacon CF, Holst JJ, Schweizer A et al.
Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.
Journal of Clinical Endocrinology and Metabolism. 2011;96(4):945-954.
https://doi.org/10.1210/jc.2010-2178Author
Vardarli, Irfan ; Nauck, Michael A ; Köthe, Lars D ; Deacon, Carolyn F ; Holst, Jens Juul ; Schweizer, Anja ; Foley, James E. / Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. In: Journal of Clinical Endocrinology and Metabolism. 2011 ; Vol. 96, No. 4. pp. 945-954.
Bibtex
@article{82074bc0ec0548e7a111086a33f77113,
title = "Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as {"}isoglycemic{"} intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes",
abstract = "Dipeptidyl peptidase-4 (DPP-4) inhibitors block the degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. The aim of the present study was to quantitatively assess the incretin effect after treatment with the DPP-4 inhibitor vildagliptin (V) or placebo (P) in patients with type 2 diabetes.",
keywords = "Adamantane, Administration, Oral, Adult, Aged, Blood Glucose, Cross-Over Studies, Diabetes Mellitus, Type 2, Dipeptidyl Peptidase 4, Dipeptidyl-Peptidase IV Inhibitors, Female, Glucose, Humans, Incretins, Injections, Intravenous, Insulin, Male, Middle Aged, Nitriles, Pyrrolidines, Up-Regulation",
author = "Irfan Vardarli and Nauck, {Michael A} and K{\"o}the, {Lars D} and Deacon, {Carolyn F} and Holst, {Jens Juul} and Anja Schweizer and Foley, {James E}",
year = "2011",
doi = "10.1210/jc.2010-2178",
language = "English",
volume = "96",
pages = "945--954",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Oxford University Press",
number = "4",
}
RIS
TY - JOUR
T1 - Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes
AU - Vardarli, Irfan
AU - Nauck, Michael A
AU - Köthe, Lars D
AU - Deacon, Carolyn F
AU - Holst, Jens Juul
AU - Schweizer, Anja
AU - Foley, James E
PY - 2011
Y1 - 2011
N2 - Dipeptidyl peptidase-4 (DPP-4) inhibitors block the degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. The aim of the present study was to quantitatively assess the incretin effect after treatment with the DPP-4 inhibitor vildagliptin (V) or placebo (P) in patients with type 2 diabetes.
AB - Dipeptidyl peptidase-4 (DPP-4) inhibitors block the degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. The aim of the present study was to quantitatively assess the incretin effect after treatment with the DPP-4 inhibitor vildagliptin (V) or placebo (P) in patients with type 2 diabetes.
KW - Adamantane
KW - Administration, Oral
KW - Adult
KW - Aged
KW - Blood Glucose
KW - Cross-Over Studies
KW - Diabetes Mellitus, Type 2
KW - Dipeptidyl Peptidase 4
KW - Dipeptidyl-Peptidase IV Inhibitors
KW - Female
KW - Glucose
KW - Humans
KW - Incretins
KW - Injections, Intravenous
KW - Insulin
KW - Male
KW - Middle Aged
KW - Nitriles
KW - Pyrrolidines
KW - Up-Regulation
U2 - 10.1210/jc.2010-2178
DO - 10.1210/jc.2010-2178
M3 - Journal article
C2 - 21239518
VL - 96
SP - 945
EP - 954
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 4
ER -
